Bristol Myers Squibb forecasts upbeat 2026 results behind strategic Eliquis price cuts
Bristol Myers expects 2026 revenue to beat estimates as Eliquis price cuts drive growth. Strong Opdivo sales also helped top recent quarterly expectations.
洞察:
Bristol-Myers Squibb Company announced its 2026 financial guidance on February 5, 2026, forecasting total revenue between $46.0 billion and $47.5 billion. The company stated that this range is above Wall Street estimates and includes specific revenue and adjusted earnings per share ranges. This announcement, which is a company-level development, reflects a strategic response to US 
US Medicare price negotiations established under the Inflation Reduction Act.
US Medicare price negotiations established under the Inflation Reduction Act.
